. 2003 Apr;89(4):451–458. doi: 10.1136/heart.89.4.451

Table 4.

Statin based trials of lipid lowering in subjects with coronary heart disease (angiographic trials)

Angiographic trials confirming reduced CAD progression	Treatments	Duration
Baseline mean cholesterol 4.2–9.9 mmol/l. Lipid reduction: cholesterol −13% to −53%, triglyceride −8% to −27%.
Familial Atherosclerosis Treatment Study (FATS)(1990)^w19	Nicotinic acid + colestipol	2.5 years
	Lovastatin + colestipol

University of California, San Francisco Arteriosclerosis Specialised Center of Research Intervention Trial (UCSF-SCOR) (1990)^w20	Colestipol/nicotinic acid/lovastatin	2 years

Monitored Atherosclerosis Regression Study (MARS) (1993)^w21	Lovastatin	2.2 years

Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) (1994)^w22	Lovastatin	2 years

Stanford Coronary Risk Intervention Project (SCRIP) (1994)^w23	Exercise + colestipol/nicotinic acid/gemfibrozil/ lovastatin/probucol	4 years

Multicenter Anti-Atheroma Study (MAAS) (1994)^w24	Simvastatin	4 years

Familial Hypercholesterolaemia Regression Study (FHRS) (1995)^w25	LDL apheresis + simvastatin	2.1 years
	Colestipol + simvastatin
Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC 1) (1995)^w26	Pravastatin	3 years

Regression Growth Evaluation Statin Study (REGRESS) (1995)^w27	Pravastatin	2 years

LDL-Apheresis Atherosclerosis Regression Study (LAARS) (1996)^w28	LDL apheresis + simvastatin	2 years
	Simvastatin

Lipoprotein and Coronary Atherosclerosis Study (LCAS) (1997)^w29	Fluvastatin	2.5 years
	Fluvastatin + cholestyramine

Post Coronary Artery Bypass Graft Trial (Post-CABG) (1997)^w30	Lovastatin	4.3 years (reduced rate of revascularisation)

HDL-Atherosclerosis Treatment Study (HATS) (2001)^w31	Simvastatin + niacin	3 years
	Antioxidants
	Simvastatin + niacin + antioxidants

Angiographic trial not confirming reduced CAD progression	Treatment	Duration
Baseline mean cholesterol 5.5 mmol/l. Lipid reduction: cholesterol −26%, triglyceride −20%.
Harvard Atherosclerosis Reversibility Project (HARP) Group (1994)^w32	Pravastatin/nicotinic acid/cholestyramine/gemfibrozil	2.5 years